Alkermes Plc (ALKS)

NASDAQ
19.28
+1.07(+5.88%)
  • Volume:
    1,528,921
  • Bid/Ask
    18.54/19.39
  • Day's Range
    18.02 - 19.34

ALKS Overview

Prev. Close
19.28
Day's Range
18.02 - 19.34
Revenue
1.04B
Open
18.44
52 wk Range
11.98 - 23.92
EPS
-0.7
Volume
1,528,921
Market Cap
3.07B
Dividend (Yield)
N/A (N/A)
Average Volume (3m)
1,398,514
P/E Ratio
N/A
Beta
0.92
1-Year Change
1.53%
Shares Outstanding
159,237,889
Next Earnings Date
28 Apr 2021
What is your sentiment on Alkermes Plc?
or
Market is currently closed. Voting is open during market hours.

Alkermes Plc News

Technical Summary

Type
5 Min
15 Min
Hourly
Daily
Monthly
Moving AveragesStrong BuyStrong BuyBuySellSell
Technical IndicatorsStrong BuyStrong BuyStrong BuyStrong SellSell
SummaryStrong BuyStrong BuyStrong BuyStrong SellSell

Alkermes Plc Company Profile

Alkermes Plc Company Profile

Employees
2245

Alkermes plc is a biopharmaceutical company. The Company is engaged in the researching, developing and commercializing pharmaceutical products that are designed to address medical needs of patients in therapeutic areas. The Company has a portfolio of marketed drug products and a clinical pipeline of products that address central nervous system (CNS) disorders, such as schizophrenia, depression, addiction and multiple sclerosis (MS). The Company's products include ARISTADA, VIVITROL, INVEGA SUSTENNA, XEPLION, INVEGA TRINZA, TREVICTA, RISPERDAL CONSTA, AMPYRA, FAMPYRA, BYDUREON, Aripiprazole lauroxil, ALKS 5461, ALKS 3831, ALKS 8700, ALKS 6428, ALKS 4230 and ALKS 7119. The Company's product platforms include injectable extended-release microsphere technology, LinkeRx technology, NanoCrystal technology and oral controlled release (OCR) technology. ARISTADA is an extended-release intramuscular injectable suspension for the treatment of schizophrenia.

Read More
    Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All CFDs (stocks, indexes, futures), cryptocurrencies, and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn't bear any responsibility for any trading losses you might incur as a result of using this data.
    Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.